Revolution Medicines Stock Soars 250% Despite No Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Source: Fool
- Stock Performance: Revolution Medicines' shares have surged over 250% in the past year, with a market cap nearing $30 billion, despite the company currently being unprofitable and generating no revenue, indicating high market expectations for future growth.
- Promising Drugs: Although the company lacks approved products, its drug daraxonrasib shows significant potential in treating pancreatic cancer, with clinical studies indicating a median survival extension from 6.7 months to 13.2 months, suggesting high future sales potential.
- Market Expectations: Analysts project that daraxonrasib could peak at over $7 billion in sales, and additional cancer drugs like zoldonrasib and elironrasib may generate billions more, making the current high valuation appear more justifiable in light of potential growth.
- Investment Risks: While there is considerable excitement around Revolution Medicines, investors should be cautious as the current stock price may reflect excessive future growth expectations, with uncertainties regarding cash flow, drug approvals, and market competition posing risks of significant price volatility.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 154.630
Low
67.00
Averages
86.00
High
147.00
Current: 154.630
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Goldman Sachs' Hedge Fund VIP List Includes Micron Technology
- Hedge Fund Favoritism: Micron Technology has made it to Goldman Sachs' coveted Hedge Fund VIP list, indicating strong interest from professional traders in its data and storage chips, reflecting optimistic market expectations for future growth.
- Outstanding Market Performance: The VIP basket has risen 10% year-to-date, outperforming the S&P 500's 9% gain, suggesting that hedge fund investment strategies are excelling in the current market environment, thereby boosting investor confidence in Micron.
- Stock Surge: Micron's shares soared 19% on Tuesday alone, pushing its market value past $1 trillion for the first time, primarily driven by insatiable AI demand for its memory chips, showcasing the company's competitiveness in emerging technologies.
- Analyst Optimism: UBS has tripled its price target on Micron to $1,625, believing that the market will start to assign a more 'normal' multiple to the stock, indicating that it is likely to continue rising as structural changes driven by AI unfold.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Revolution Medicines Q1 2026 Earnings Call Insights
- Survival Rate Improvement: In the RASolute 302 trial, daraxonrasib monotherapy demonstrated a significant improvement in overall survival compared to chemotherapy, achieving a median survival exceeding one year and a 60% reduction in the risk of death in the intent-to-treat population, marking a major breakthrough in treating metastatic pancreatic cancer.
- FDA Application Plans: The company intends to submit a new drug application under the FDA Commissioner's National Priority Voucher Program, with CEO Goldsmith emphasizing this as a strategic priority, while the FDA has also approved the initiation of an expanded access treatment protocol, enhancing patient treatment opportunities.
- Improved Financial Position: As of Q1 2026, the company reported $1.9 billion in cash and investments, bolstered by $2.1 billion in net proceeds from April offerings, significantly strengthening its financial position and providing funding for ongoing R&D and market initiatives.
- Rising Operating Expenses: Due to accelerated R&D efforts, Q1 R&D expenses reached $344 million, up from $205.7 million year-over-year, while G&A expenses increased from $35 million to $101.3 million, resulting in a net loss of $453.8 million, reflecting the company's commitment to advancing clinical trials and market readiness.
See More
Revolution (RVMD) Q1 2026 Earnings Transcript
See More
Revolution Medicines Reports Clinical Trial Results for Daraxonrasib
- Clinical Trial Progress: Revolution Medicines published data from the Phase 1/2 trial of daraxonrasib in the NEJM, demonstrating promising antitumor activity in previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma patients, supporting the initiation of its global Phase 3 trial.
- Survival Rate Improvement: The RASolute 302 trial showed daraxonrasib provided unprecedented overall survival benefits compared to standard chemotherapy, indicating its potential to offer new treatment options for pancreatic cancer patients.
- FDA Breakthrough Therapy Designation: Daraxonrasib received Breakthrough Therapy and Orphan Drug Designation from the FDA, highlighting its significant potential in treating metastatic pancreatic ductal adenocarcinoma, which boosts investor and market confidence.
- Strong Market Demand: Pancreatic cancer is one of the deadliest cancers in the U.S., with approximately 60,000 diagnosed and 50,000 deaths annually, making daraxonrasib's development crucial to meet this high demand and improve patient survival and quality of life.
See More
Goldman Sachs' Hedge Fund VIP List Includes Micron Technology
- Hedge Fund Favoritism: Micron Technology has made it to Goldman Sachs' coveted Hedge Fund VIP list, indicating strong interest from professional traders in its data and storage chips, reflecting optimistic market expectations for future growth.
- Outstanding Market Performance: The VIP basket has risen 10% year-to-date, outperforming the S&P 500's 9% gain, suggesting that hedge fund investment strategies are excelling in the current market environment, thereby boosting investor confidence in Micron.
- Stock Surge: Micron's shares soared 19% on Tuesday alone, pushing its market value past $1 trillion for the first time, primarily driven by insatiable AI demand for its memory chips, showcasing the company's competitiveness in emerging technologies.
- Analyst Optimism: UBS has tripled its price target on Micron to $1,625, believing that the market will start to assign a more 'normal' multiple to the stock, indicating that it is likely to continue rising as structural changes driven by AI unfold.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Revolution Medicines Q1 2026 Earnings Call Insights
- Survival Rate Improvement: In the RASolute 302 trial, daraxonrasib monotherapy demonstrated a significant improvement in overall survival compared to chemotherapy, achieving a median survival exceeding one year and a 60% reduction in the risk of death in the intent-to-treat population, marking a major breakthrough in treating metastatic pancreatic cancer.
- FDA Application Plans: The company intends to submit a new drug application under the FDA Commissioner's National Priority Voucher Program, with CEO Goldsmith emphasizing this as a strategic priority, while the FDA has also approved the initiation of an expanded access treatment protocol, enhancing patient treatment opportunities.
- Improved Financial Position: As of Q1 2026, the company reported $1.9 billion in cash and investments, bolstered by $2.1 billion in net proceeds from April offerings, significantly strengthening its financial position and providing funding for ongoing R&D and market initiatives.
- Rising Operating Expenses: Due to accelerated R&D efforts, Q1 R&D expenses reached $344 million, up from $205.7 million year-over-year, while G&A expenses increased from $35 million to $101.3 million, resulting in a net loss of $453.8 million, reflecting the company's commitment to advancing clinical trials and market readiness.
See More
Revolution (RVMD) Q1 2026 Earnings Transcript
See More
Revolution Medicines Reports Clinical Trial Results for Daraxonrasib
- Clinical Trial Progress: Revolution Medicines published data from the Phase 1/2 trial of daraxonrasib in the NEJM, demonstrating promising antitumor activity in previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma patients, supporting the initiation of its global Phase 3 trial.
- Survival Rate Improvement: The RASolute 302 trial showed daraxonrasib provided unprecedented overall survival benefits compared to standard chemotherapy, indicating its potential to offer new treatment options for pancreatic cancer patients.
- FDA Breakthrough Therapy Designation: Daraxonrasib received Breakthrough Therapy and Orphan Drug Designation from the FDA, highlighting its significant potential in treating metastatic pancreatic ductal adenocarcinoma, which boosts investor and market confidence.
- Strong Market Demand: Pancreatic cancer is one of the deadliest cancers in the U.S., with approximately 60,000 diagnosed and 50,000 deaths annually, making daraxonrasib's development crucial to meet this high demand and improve patient survival and quality of life.
See More
